218 related articles for article (PubMed ID: 18710896)
1. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
Yokoo S; Masuda S; Yonezawa A; Terada T; Katsura T; Inui K
Drug Metab Dispos; 2008 Nov; 36(11):2299-306. PubMed ID: 18710896
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.
Jong NN; Nakanishi T; Liu JJ; Tamai I; McKeage MJ
J Pharmacol Exp Ther; 2011 Aug; 338(2):537-47. PubMed ID: 21606177
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.
Meynard D; Le Morvan V; Bonnet J; Robert J
Oncol Rep; 2007 May; 17(5):1213-21. PubMed ID: 17390068
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
7. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
8. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells.
Chiu SJ; Hsu TS; Chao JI
Toxicol Lett; 2006 Dec; 167(2):122-30. PubMed ID: 17045763
[TBL] [Abstract][Full Text] [Related]
9. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
11. Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer.
Ota K; Ito K; Akahira J; Sato N; Onogawa T; Moriya T; Unno M; Abe T; Niikura H; Takano T; Yaegashi N
Int J Gynecol Pathol; 2007 Jul; 26(3):334-40. PubMed ID: 17581421
[TBL] [Abstract][Full Text] [Related]
12. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).
Bourdet DL; Pritchard JB; Thakker DR
J Pharmacol Exp Ther; 2005 Dec; 315(3):1288-97. PubMed ID: 16141367
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
14. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
15. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer.
Iwatsuki M; Mimori K; Yokobori T; Tanaka F; Tahara K; Inoue H; Baba H; Mori M
J Surg Oncol; 2009 Sep; 100(3):261-6. PubMed ID: 19330779
[TBL] [Abstract][Full Text] [Related]
16. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3.
Hayer-Zillgen M; Brüss M; Bönisch H
Br J Pharmacol; 2002 Jul; 136(6):829-36. PubMed ID: 12110607
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.
Talieri M; Mathioudaki K; Prezas P; Alexopoulou DK; Diamandis EP; Xynopoulos D; Ardavanis A; Arnogiannaki N; Scorilas A
Thromb Haemost; 2009 Apr; 101(4):741-7. PubMed ID: 19350120
[TBL] [Abstract][Full Text] [Related]
19. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).
Burger H; Zoumaro-Djayoon A; Boersma AW; Helleman J; Berns EM; Mathijssen RH; Loos WJ; Wiemer EA
Br J Pharmacol; 2010 Feb; 159(4):898-908. PubMed ID: 20067471
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
Mandal R; Sawyer MB; Li XF
Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
